|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This indication is an extension to the original licence in the relapsed/refractory setting.|
|Rapid review commissioned||02/08/2016|
|Rapid review completed||24/08/2016|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended|
Not considered cost-effective due to non-submission of full pharmacoeconomic assessment.